{
    "clinical_study": {
        "@rank": "36662", 
        "arm_group": [
            {
                "arm_group_label": "MK-3102", 
                "arm_group_type": "Experimental", 
                "description": "MK-3102 25 mg administered orally once weekly and matching placebo to sitagliptin administered orally once daily for 24 weeks (Phase A), followed by MK-3102 25 mg administered orally once weekly for 28 weeks (Phase B)."
            }, 
            {
                "arm_group_label": "Sitagliptin", 
                "arm_group_type": "Active Comparator", 
                "description": "Sitagliptin 50 mg administered orally once daily and matching placebo to MK-3102 administered orally once weekly for 24 weeks (Phase A), followed by MK-3102 25 mg administered orally once weekly for 28 weeks (Phase B)."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo to MK-3102 administered orally once weekly and matching placebo to sitagliptin administered orally once daily for 24 weeks (Phase A), followed by MK-3102 25 mg administered orally once weekly for 28 weeks (Phase B)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the efficacy of MK-3102 25 mg weekly (as monotherapy)\n      compared with sitagliptin 50 mg daily and placebo, and the long term safety (up to 52 weeks)\n      of MK-3102 25 mg weekly. The primary hypotheses are that after 24 weeks 1) MK-3102 25 mg\n      weekly provides a greater reduction from baseline in glycosylated hemoglobin (HbA1c)\n      compared with placebo, and 2) the mean change from baseline in HbA1c in participants treated\n      with MK-3102 25 mg weekly is non-inferior compared with that in participants treated with\n      sitagliptin 50 mg daily."
        }, 
        "brief_title": "MK-3102 Phase III Clinical Trial - Placebo- and Sitagliptin-controlled Monotherapy Study in Japanese Participants With Type 2 Diabetes Mellitis (MK-3102-020)", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Has type 2 diabetes mellitus\n\n        Exclusion Criteria:\n\n          -  History of type 1 diabetes mellitus or a history of ketoacidosis\n\n          -  History of any of the following medications: thiazolidinediones and/or insulin within\n             12 weeks prior to study participation, MK-3102 and/or sitagliptin anytime"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "414", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01703221", 
            "org_study_id": "3102-020", 
            "secondary_id": "132239"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "MK-3102", 
                    "Sitagliptin", 
                    "Placebo"
                ], 
                "description": "MK-3102 25 mg capsule administered orally once weekly", 
                "intervention_name": "MK-3102", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sitagliptin", 
                "description": "Sitagliptin 50 mg tablet administered orally once daily", 
                "intervention_name": "Sitagliptin", 
                "intervention_type": "Drug", 
                "other_name": "Januvia\u00ae"
            }, 
            {
                "arm_group_label": [
                    "Sitagliptin", 
                    "Placebo"
                ], 
                "description": "Matching placebo to MK-3102 25 mg capsule administered orally once weekly", 
                "intervention_name": "Placebo to MK-3102", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MK-3102", 
                    "Placebo"
                ], 
                "description": "Matching placebo to sitagliptin 50 mg tablet administered orally once daily", 
                "intervention_name": "Placebo to sitagliptin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sitagliptin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 12, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Phase III, Multicenter, Randomized, Placebo- and Sitagliptin-controlled, Parallel-group, Double-blinded Study and Subsequent Open-label, Extension Study to Assess the Safety and Efficacy of MK-3102 in Japanese Patients With Type 2 Diabetes Mellitis Who Have Inadequate Glycemic Control on Diet/Exercise Therapy", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from baseline for hemoglobin A1c (HbA1c)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Percentage of participants who experienced at least one adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 24"
            }, 
            {
                "measure": "Percentage of participants who experienced at least one adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 52"
            }, 
            {
                "measure": "Percentage of participants who discontinued from the study due to an adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 24"
            }, 
            {
                "measure": "Percentage of participants who discontinued from the study due to an adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 52"
            }
        ], 
        "removed_countries": {
            "country": "Japan"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01703221"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline for 2-hour post meal glucose (PMG)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Change from baseline for fasting plasma glucose (FPG)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}